Sulfhydryl-based tumor antigen-carrier protein conjugates stimulate superior antitumor immunity against B cell lymphomas

Journal of Immunology

Volumn 181, Issue 6, 2008, Pages 4131-4140

  Betting, David J ^a   Kafi, Kamran ^a   Abdollahi Fard, Alireza ^a   Hurvitz, Sara A ^a   Timmerman, John M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GLUTARALDEHYDE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN IDIOTYPE; KEYHOLE LIMPET HEMOCYANIN; MALEIMIDE; CARRIER PROTEIN; CROSS LINKING REAGENT; MALEIMIDE DERIVATIVE; TUMOR ANTIGEN; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B CELL LYMPHOMA; CANCER IMMUNIZATION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONJUGATION; CONTROLLED STUDY; DRUG EFFICACY; EFFECTOR CELL; HUMORAL IMMUNITY; LYSOSOME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; TUMOR IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; CANCER TRANSPLANTATION; CD4+ T LYMPHOCYTE; COMPARATIVE STUDY; HUMAN; IMMUNOLOGY; METABOLISM; PASSIVE IMMUNIZATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CARRIER PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; GLUTARAL; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA, B-CELL; MALEIMIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; NEOPLASM TRANSPLANTATION; VACCINES, CONJUGATE;

EID: 56149108713     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.181.6.4131     Document Type: Article

References (57)

1. Timmerman, J. M. 2003. Immunotherapy for lymphomas. Int. J. Hematol. 77: 444-455.
2. Levy, R., and J. Dilley. 1978. Rescue of immunoglobulin secretion from human neoplastic lymphoid cells by somatic cell hybridization. Proc. Natl. Acad. Sci. USA 75: 2411-2415. (Pubitemid 8349450)
3. Hawkins, R. E., D. Zhu, M. Ovecka, G. Winter, T. J. Hamblin, A. Long, and F. K. Stevenson. 1994. Idiotypic vaccination against human B-cell lymphoma: rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines. Blood 83: 3279-3288.
4. Hurvitz, S. A., and J. M. Timmerman. 2005. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin. Biol. Ther. 5: 841-852.
5. Maloney, D. G., M. S. Kaminski, D. Burowski, J. Haimovich, and R. Levy. 1985. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 4: 191-209.
6. Kaminski, M. S., K. Kitamura, D. G. Maloney, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: inhibition of tumor immunity by free idiotype protein. J. Immunol. 138: 1289-1296.
7. Campbell, M. J., W. Carroll, S. Kon, K. Thielemans, J. B. Rothbard, S. Levy, and R. Levy. 1987. Idiotype vaccination against murine B cell lymphoma: humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139: 2825-2833.
8. George, A. J., S. G. Folkard, T. J. Hamblin, and F. K. Stevenson. 1988. Idiotypic vaccination as a treatment for a B cell lymphoma. J. Immunol. 141: 2168-2174.
9. Campbell, M. J., L. Esserman, and R. Levy. 1988. Immunotherapy of established murine B cell lymphoma: combination of idiotype immunization and cyclophosphamide. J. Immunol. 141: 3227-3233.
10. Campbell, M. J., L. Esserman, N. E. Byars, A. C. Allison, and R. Levy. 1990. Idiotype vaccination against murine B cell lymphoma: humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145: 1029-1036.
11. Kwak, L. W., H. A. Young, R. W. Pennington, and S. D. Weeks. 1996. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93: 10972-10977.
12. Timmerman, J. M., and R. Levy. 2000. Linkage of foreign carrier protein to a self-tumor antigen enhances the immunogenicity of a pulsed dendritic cell vaccine. J. Immunol. 164: 4797-4803.
13. Kwak, L. W., M. J. Campbell, D. K. Czerwinski, S. Hart, R. A. Miller, and R. Levy. 1992. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N. Engl. J. Med. 327: 1209-1215.
14. Kwak, L. W., D. D. Taub, P. L. Duffey, W. I. Bensinger, E. M. Bryant, C. W. Reynolds, and D. L. Longo. 1995. Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor. Lancet 345: 1016-1020.
15. Hsu, F. J., C. Benike, F. Fagnoni, T. M. Liles, D. Czerwinski, B. Taidi, E. G. Engleman, and R. Levy. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2: 52-58.
16. Hsu, F. J., C. B. Caspar, D. Czerwinski, L. W. Kwak, T. M. Liles, A. Syrengelas, B. Taidi-Laskowski, and R. Levy. 1997. Tumor-specific idiotype vaccines in the treatment of patients with B- cell lymphoma: long-term results of a clinical trial. Blood 89: 3129-3135. (Pubitemid 27229795)
17. Bendandi, M., C. D. Gocke, C. B. Kobrin, F. A. Benko, L. A. Sternas, R. Pennington, T. M. Watson, C. W. Reynolds, B. L. Gause, P. L. Duffey, et al. 1999. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat. Med. 5: 1171-1177. (Pubitemid 29474422)
18. Timmerman, J. M., D. Czerwinski, B. Taid, A. Van Beckhoven, J. Vose, D. Ingolia, L. Kunkel, D. Denney, and R. Levy. 2000. A phase I/II trial to evaluate the immunogenicity of recombinant Idiotype protein vaccines for the treatment of non-Hodgkin's lymphoma (NHL). Blood 96: 578a (Abstr.).
19. Timmerman, J., J. Vose, L. Kunkel, P. Bierman, D. Czerwinski, M. Hohenstein, D. Ingolia, D. Denney, and R. Levy. 2001. A phase 2 study demonstrating recombinant Idiotype vaccine elicits specific anti-Idiotype immune responses in aggressive non-Hodgkin's lymphoma. Blood 98: 341a (Abstr.). (Pubitemid 33787536)
20. Timmerman, J. M., D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99: 1517-1526.
21. Barrios, Y., R. Cabrera, R. Yanez, M. Briz, A. Plaza, R. Fores, M. N. Fernandez, and F. Diaz-Espada. 2002. Anti-idiotypic vaccination in the treatment of low-grade B-cell lymphoma. Haematologica 87: 400-407. (Pubitemid 34297547)
22. Koc, O., C. Redfern, P. H. Wiernik, F. Rosenfelt, J. Winter, T. H. Guthrie, L. Kaplan, P. Holman, J. Densmore, J. Hainsworth, et al. 2004. Id/KLH vaccine (FavIdTM) following treatment with rituximab: an analysis of response rate improvement (RRI) and time-to-progression (TTP) in follicular lymphoma (FL). Blood 104: 170a.
23. Inoges, S., M. Rodriguez-Calvillo, N. Zabalegui, A. Lopez-Diaz de Cerio, H. Villanueva, E. Soria, L. Suarez, A. Rodriguez-Caballero, F. Pastor, R. Garcia-Munoz, et al. 2006. Clinical benefit associated with idiotypic vaccination in patients with follicular lymphoma. J. Natl. Cancer Inst. 98: 1292-1301. (Pubitemid 44530725)
24. Redfern, C. H., T. H. Guthrie, A. Bessudo, J. J. Densmore, P. R. Holman, N. Janakiraman, J. P. Leonard, R. L. Levy, R. G. Just, M. R. Smith, et al. 2006. Phase II trial of idiotype vaccination in previously treated patients with indolent non-Hodgkin's lymphoma resulting in durable clinical responses. J. Clin. Oncol. 24: 3107-3112.
25. Timmerman, J. M., and R. L. Levy. 2000. The history of the development of vaccines for lymphoma. Clin. Lymphoma 1: 129-139.
26. Hurvitz, S. A., and J. M. Timmerman. 2005. Current status of therapeutic vaccines for non-Hodgkin's lymphoma. Curr. Opin. Oncol. 17: 432-440. (Pubitemid 41224922)
27. Timmerman, J. M., R. Levy, D. K. Czerwinski, D. Ingolia, D. Denney, and L. Kunkel. 2002. A phase 2 trial to evaluate the efficacy of recombinant idiotype vaccines in untreated follicular lymphoma in the "watch-and- wait" period. Proc. Am. Soc. Clin. Oncol. 21: 4a, abstract 13.
28. Biragyn, A., K. Tani, M. C. Grimm, S. Weeks, and L. W. Kwak. 1999. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17: 253-258. (Pubitemid 29122633)
29. Biragyn, A., and L. W. Kwak. 2001. Models for lymphoma. In Current Protocols in Immunology. A. M. Kruisbeek, J. E. Coligan, D. H. Margulies, E. M. Shevach, W. Strober, and R. Coico, eds. John Wiley & Sons, Hoboken, NJ, pp. 20.26.21-20.26.30.
30. Migneault, I., C. Dartiguenave, M. J. Bertrand, and K. C. Waldron. 2004. Glutaraldehyde: behavior in aqueous solution, reaction with proteins, and application to enzyme crosslinking. BioTechniques 37:790-796, 798-802. (Pubitemid 39488459)
31. Armstrong, A. C., S. Dermime, C. G. Allinson, T. Bhattacharyya, K. Mulryan, K. R. Gonzalez, P. L. Stern, and R. E. Hawkins. 2002. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J. Immunol. 168: 3983-3991.
32. Yoshitake, S., Y. Yamada, E. Ishikawa, and R. Masseyeff. 1979. Conjugation of glucose oxidase from Aspergillus niger and rabbit antibodies using N-hydroxysuccinimide ester of N-(4-carboxycyclohexylmethyl)-maleimide. Eur. J. Biochem. 101: 395-399. (Pubitemid 10151297)
33. Yoshitake, S., M. Imagawa, E. Ishikawa, Y. Niitsu, I. Urushizaki, M. Nishiura, R. Kanazawa, H. Kurosaki, S. Tachibana, N. Nakazawa, and H. Ogawa. 1982. Mild and efficient conjugation of rabbit Fab′ and horseradish peroxidase using a maleimide compound and its use for enzyme immunoassay. J. Biochem. 92: 1413-1424.
34. Hashida, S., M. Imagawa, S. Inoue, K. H. Ruan, and E. Ishikawa. 1984. More useful maleimide compounds for the conjugation of Fab′ to horseradish peroxidase through thiol groups in the hinge. J. Appl. Biochem. 6: 56-63.
35. Peeters, J. M., T. G. Hazendonk, E. C. Beuvery, and G. I. Tesser. 1989. Comparison of four bifunctional reagents for coupling peptides to proteins and the effect of the three moieties on the immunogenicity of the conjugates. J. Immunol. Methods 120: 133-143.
36. Kim, K. J., C. Kanellopoulos-Langevin, R. M. Merwin, D. H. Sachs, and R. Asofsky. 1979. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122: 549-554. (Pubitemid 9089211)
37. Bergman, Y., and J. Haimovich. 1977. Characterization of a carcinogen-induced murine B lymphocyte cell line of C3H/eB origin. Eur. J. Immunol. 7: 413-417. (Pubitemid 8149366)
38. Warnke, R. A., S. Slavin, R. L. Coffman, E. C. Butcher, M. R. Knapp, S. Strober, and I. L. Weissman. 1979. The pathology and homing of a transplantable murine B cell leukemia (BCL1). J. Immunol. 123: 1181-1188.
39. Timmerman, J. M., C. B. Caspar, S. L. Lambert, A. D. Syrengelas, and R. Levy. 2001. Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 97: 1370-1377.
40. Brissinck, J., C. Demanet, M. Moser, O. Leo, and K. Thielemans. 1991. Treatment of mice bearing BCL1 lymphoma with bispecific antibodies. J. Immunol. 147: 4019-4026.
41. Levitsky, H. I., J. Montgomery, M. Ahmadzadeh, K. Staveley-O'Carroll, F. Guarnieri, D. L. Longo, and L. W. Kwak. 1996. Immunization with granulocyte-macrophage colony-stimulating factor-transduced, but not B7-1-transduced, lymphoma cells primes idiotype-specific T cells and generates potent systemic antitumor immunity. J. Immunol. 156: 3858-3865. (Pubitemid 26137674)
42. Franki, S. N., K. K. Steward, D. J. Betting, K. Kafi, R. E. Yamada, and J. M. Timmerman. 2008. Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo. Blood 111: 1504-1511.
43. Ahuja, A., J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351-3361.
44. Delamarre, L., M. Pack, H. Chang, I. Mellman, and E. S. Trombetta. 2005. Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science 307: 1630-1634. (Pubitemid 40354746)
45. Kaminski, M. S., K. Kitamura, D. G. Maloney, M. J. Campbell, and R. Levy. 1986. Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma: a study of hybridoma class switch variants. J. Immunol. 136: 1123-1130.
46. George, A. J., A. L. Tutt, and F. K. Stevenson. 1987. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1. J. Immunol. 138: 628-634.
47. Eisenlohr, L. C., and J. L. Rothstein. 2005. Antigen processing and presentation. Cancer Treat. Res. 123: 3-36.
48. Biragyn, A., M. Surenhu, D. Yang, P. A. Ruffini, B. A. Haines, E. Klyushnenkova, J. J. Oppenheim, and L. W. Kwak. 2001. Mediators of innate immunity that target immature, but not mature, dendritic cells induce antitumor immunity when genetically fused with nonimmunogenic tumor antigens. J. Immunol. 167: 6644-6653. (Pubitemid 33081603)
49. Weng, W. K., D. Czerwinski, J. Timmerman, F. J. Hsu, and R. Levy. 2004. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J. Clin. Oncol. 22: 4717-4724.
50. Zhang, S., L. A. Graeber, F. Helling, G. Ragupathi, S. Adluri, K. O. Lloyd, and P. O. Livingston. 1996. Augmenting the immunogenicity of synthetic MUC1 peptide vaccines in mice. Cancer Res. 56: 3315-3319. (Pubitemid 26242982)
51. Musselli, C., P. O. Livingston, and G. Ragupathi. 2001. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience. J. Cancer Res. Clin. Oncol. 127 (Suppl. 2): R20-R26. (Pubitemid 33739047)
52. Gilewski, T., S. Adluri, G. Ragupathi, S. Zhang, T. J. Yao, K. Panageas, M. Moynahan, A. Houghton, L. Norton, and P. O. Livingston. 2000. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. Clin. Cancer Res. 6: 1693-1701. (Pubitemid 30305061)
53. Kirkley, J. E., A. L. Goldstein, and P. H. Naylor. 2001. Effect of peptide-carrier coupling on peptide-specific immune responses. Immunobiology 203: 601-615.
54. Vitteta, E. S., and P. E. Thorpe. 1991. Section 21.2: immunotoxins. In Biologic Therapy of Cancer. V. T. DeVita, S. Hellman, and S. A. Rosenberg, eds. J.B. Lippincott Company, Philadelphia, pp. 482-495.
55. Grossbard, M. L., A. S. Freedman, J. Ritz, F. Coral, V. S. Goldmacher, L. Eliseo, N. Spector, K. Dear, J. M. Lambert, W. A. Blattler, et al. 1992. Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion. Blood 79: 576-585.
56. Okada, C. Y., C. P. Wong, D. W. Denney, and R. Levy. 1997. TCR vaccines for active immunotherapy of T cell malignancies. J. Immunol. 159: 5516-5527. (Pubitemid 127470080)
57. Rosenberg, S. A. 2001. Progress in human tumour immunology and immunotherapy. Nature 411: 380-384.